Jeffrey M Greeson1, David R Gettes1, Sergei Spitsin2, Benoit Dubé1, Tami D Benton3, Kevin G Lynch1, Steven D Douglas4, Dwight L Evans5. 1. Departments of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania. 2. Division of Allergy and Immunology, The Children's Hospital of Philadelphia Research Institute, Philadelphia, Pennsylvania. 3. Departments of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania; Department of Child and Adolescent Psychiatry and Behavioral Science, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. 4. Pediatrics, University of Pennsylvania, Philadelphia, Pennsylvania; Division of Allergy and Immunology, The Children's Hospital of Philadelphia Research Institute, Philadelphia, Pennsylvania. 5. Departments of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania; Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Neuroscience, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: dlevans@mail.med.upenn.edu.
Abstract
BACKGROUND: This study investigated whether the selective serotonin reuptake inhibitor (SSRI) citalopram downregulates the expression of the human immunodeficiency virus (HIV) receptor cluster of differentiation 4 (CD4) and coreceptors chemokine receptor type 5 and chemokine-related receptor type 4 (CCR5 and CXCR4) on peripheral blood mononuclear cells (PBMCs) and macrophages ex vivo as a potential mechanism of reducing susceptibility to HIV infection. METHODS: The sample included 150 participants 18-58 years old (59% women, 65% African American, 61% with depression). Monocyte-depleted PBMCs were treated with phytohemagglutinin for 72 hours and then cultured in the presence of interleukin-2 with vehicle control or the SSRI (10(-6) mol/L) for 2 hours. To generate monocyte-derived macrophages, monocytes were cultured for 7 days, after which either vehicle control or SSRI (10(-6) mol/L) was added for 2 hours. RNA was collected from both cell types, and messenger RNA expression of CD4, CCR5, and CXCR4 was measured by real-time polymerase chain reaction. RESULTS: In PBMCs, SSRI treatment decreased expression of CD4 (p = .009), CCR5 (p = .008), and CXCR4 (p < .0001). In monocyte-derived macrophages, SSRI treatment decreased expression of CD4 (p < .0001) and CXCR4 (p = .0003), but not CCR5 (p = .71). The suppressive effects of the SSRI on receptor expression did not differ as a function of depression diagnosis or depressive symptom severity. CONCLUSIONS: Treatment with the SSRI at a physiologic dose decreased CD4, CCR5, and CXCR4 expression on PBMCs and macrophages ex vivo. These findings suggest that SSRI treatment, independent of depression status, downregulates HIV receptor and coreceptor expression and may reduce susceptibility of immune cells to HIV infection and decrease inflammation. If clinical trials confirm the present findings, ultimately there may be a role for using SSRI treatment adjunctively in HIV and acquired immunodeficiency syndrome.
BACKGROUND: This study investigated whether the selective serotonin reuptake inhibitor (SSRI) citalopram downregulates the expression of the humanimmunodeficiency virus (HIV) receptor cluster of differentiation 4 (CD4) and coreceptors chemokine receptor type 5 and chemokine-related receptor type 4 (CCR5 and CXCR4) on peripheral blood mononuclear cells (PBMCs) and macrophages ex vivo as a potential mechanism of reducing susceptibility to HIV infection. METHODS: The sample included 150 participants 18-58 years old (59% women, 65% African American, 61% with depression). Monocyte-depleted PBMCs were treated with phytohemagglutinin for 72 hours and then cultured in the presence of interleukin-2 with vehicle control or the SSRI (10(-6) mol/L) for 2 hours. To generate monocyte-derived macrophages, monocytes were cultured for 7 days, after which either vehicle control or SSRI (10(-6) mol/L) was added for 2 hours. RNA was collected from both cell types, and messenger RNA expression of CD4, CCR5, and CXCR4 was measured by real-time polymerase chain reaction. RESULTS: In PBMCs, SSRI treatment decreased expression of CD4 (p = .009), CCR5 (p = .008), and CXCR4 (p < .0001). In monocyte-derived macrophages, SSRI treatment decreased expression of CD4 (p < .0001) and CXCR4 (p = .0003), but not CCR5 (p = .71). The suppressive effects of the SSRI on receptor expression did not differ as a function of depression diagnosis or depressive symptom severity. CONCLUSIONS: Treatment with the SSRI at a physiologic dose decreased CD4, CCR5, and CXCR4 expression on PBMCs and macrophages ex vivo. These findings suggest that SSRI treatment, independent of depression status, downregulates HIV receptor and coreceptor expression and may reduce susceptibility of immune cells to HIV infection and decrease inflammation. If clinical trials confirm the present findings, ultimately there may be a role for using SSRI treatment adjunctively in HIV and acquired immunodeficiency syndrome.
Authors: J Leserman; E D Jackson; J M Petitto; R N Golden; S G Silva; D O Perkins; J Cai; J D Folds; D L Evans Journal: Psychosom Med Date: 1999 May-Jun Impact factor: 4.312
Authors: Dwight L Evans; Kevin G Lynch; Tami Benton; Benoit Dubé; David R Gettes; Nancy B Tustin; Jian Ping Lai; David Metzger; Steven D Douglas Journal: Biol Psychiatry Date: 2007-10-22 Impact factor: 13.382
Authors: Manish K Jha; Abu Minhajuddin; Bharathi S Gadad; Tracy Greer; Bruce Grannemann; Abigail Soyombo; Taryn L Mayes; A John Rush; Madhukar H Trivedi Journal: Psychoneuroendocrinology Date: 2017-01-24 Impact factor: 4.905
Authors: Tessa Concepcion; Jennifer Velloza; Christopher G Kemp; Amritha Bhat; Ian M Bennett; Deepa Rao; Christina S Polyak; Julie A Ake; Allahna Esber; Nicole Dear; Jonah Maswai; John Owuoth; Valentine Sing'oei; Emmanuel Bahemana; Michael Iroezindu; Hannah Kibuuka; Pamela Y Collins Journal: AIDS Behav Date: 2022-10-09
Authors: Louise E van Eekeren; Vasiliki Matzaraki; Zhenhua Zhang; Lisa van de Wijer; Marc J T Blaauw; Marien I de Jonge; Linos Vandekerckhove; Wim Trypsteen; Leo A B Joosten; Mihai G Netea; Quirijn de Mast; Hans J P M Koenen; Yang Li; André J A M van der Ven Journal: Sci Rep Date: 2022-07-06 Impact factor: 4.996
Authors: Shariful A Syed; Eléonore Beurel; David A Loewenstein; Jeffrey A Lowell; W Edward Craighead; Boadie W Dunlop; Helen S Mayberg; Firdaus Dhabhar; W Dalton Dietrich; Robert W Keane; Juan Pablo de Rivero Vaccari; Charles B Nemeroff Journal: Neuron Date: 2018-08-23 Impact factor: 17.173
Authors: Olivia Bauer; Vladimir M Milenkovic; Sven Hilbert; Nina Sarubin; Johannes Weigl; Lisa-Marie Bahr; Thomas C Wetter; Barbara Heckel; Christian H Wetzel; Rainer Rupprecht; Caroline Nothdurfter Journal: Neuroimmunomodulation Date: 2021-01-27 Impact factor: 2.492
Authors: Sergei Spitsin; Vasiliki Pappa; Annemarie Kinder; Dwight L Evans; Jay Rappaport; Steven D Douglas Journal: Medicine (Baltimore) Date: 2021-06-11 Impact factor: 1.817